Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (60)

2024

  1. Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study

    Journal of Clinical Medicine, Vol. 13, Núm. 4

  2. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 1

2023

  1. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients

    Pharmaceutics, Vol. 15, Núm. 11

  2. Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 15

  3. Polymorphisms in VDR, CYP27B1, CYP2R1, GC and CYP24A1 Genes as Biomarkers of Survival in Non-Small Cell Lung Cancer: A Systematic Review

    Nutrients, Vol. 15, Núm. 6

2022

  1. Effect of Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway on Susceptibility to Non-Small-Cell Lung Cancer

    Nutrients, Vol. 14, Núm. 21

2021

  1. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis

    Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47

  2. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives

    Mutation Research - Reviews in Mutation Research, Vol. 788

  3. Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

    Nutrients, Vol. 13, Núm. 11

  4. Impact of a risk-sharing agreement in rheumatoid arthritis in Spain

    Health Policy, Vol. 125, Núm. 3, pp. 335-340

  5. Impact of genetic polymorphisms on the metabolic pathway of vitamin d and survival in non-small cell lung cancer

    Nutrients, Vol. 13, Núm. 11

  6. Influence of genetic polymorphisms on clinical outcomes of glatiramer acetate in multiple sclerosis patients

    Journal of Personalized Medicine, Vol. 11, Núm. 10

  7. Influence of the fcgr2a rs1801274 and fcgr3a rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  8. Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis

    Journal of Personalized Medicine, Vol. 11, Núm. 5

2020

  1. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

    Mutation Research - Reviews in Mutation Research, Vol. 785

  2. Impact of single-nucleotide polymorphisms of CTLA-4, CD80 and CD86 on the effectiveness of abatacept in patients with rheumatoid arthritis

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-17

2017

  1. Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer

    Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444

2015

  1. Differences in cancer drug assessment between Spain and the United Kingdom

    European Journal of Cancer, Vol. 51, Núm. 13, pp. 1843-1852

  2. Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(Butylcyanoacrylate) nanoparticles

    International Journal of Nanomedicine, Vol. 10, pp. 1291-1306

  3. Expression of glucose transporters in the prelaminar region of the optic-nerve head of the pig as determined by immunolabeling and tissue culture

    PLoS ONE, Vol. 10, Núm. 6